| Antiviral | Use | Manufacturer | Component | Type | Year approved |
|---|
| Abacavir | HIV | ViiV Healthcare | | Nucleoside analogue reverse transcriptase inhibitor (NRTI) | 1998 |
| Acyclovir (Aciclovir) | Herpes Simplex, chickenpox, [2] varicella zoster virus | GSK | | guanosine analogue RTI | 1981 |
| Adefovir | Hepatitis B [3] | Gilead Sciences | | RTI | 2002 (FDA), 2003 (EU) |
| Amantadine | Influenza | | | Influenza A virus M2 proton channel antagonist | 1966 |
| Ampligen | Avian Influenza | | | Immunomodulatory double-stranded RNA | 2016 (Argentina) |
| Amprenavir (Agenerase) | HIV | | | Protease inhibitor (PI) | 1999 (FDA) |
| Umifenovir (Arbidol) | Influenza | | | Hemagglutinin inhibitor | |
| Atazanavir | HIV | | | PI | 2015 (FDA) |
| Atripla (Efavirenz/emtricitabine/tenofovir) | HIV | | | - Efavirenz: Non-nucleoside RTI (NNRTI)
- Emtricitabine: NRTI
- Tenofovir disoproxil: NRTI
| 1998 |
| Baloxavir marboxil (Xofluza) [4] | Influenza A/B | | | Cap snatching endonuclease inhibitor | 2018 |
| Biktarvy (Bictegravir/emtricitabine/tenofovir alafenamide) | HIV | Gilead Sciences | | - Bictegravir: INSTI
- Emtricitabine: NRTI
- Tenofovir alafenamide: NRTI
| 2018 |
| Boceprevir | Hepatitis C genotype 1 [5] | Schering-Plough, then Merck Group | | Protease inhibitor | - FDA approved 2011
- Withdrawn 2015
|
| Bulevirtide | Hepatitis D/B | | | Sodium/bile acid cotransporter inactivator | 2020 (EU) |
| Cidofovir | AIDS | | | Viral DNA Polymerase inhibitor | 1996 (FDA) |
| Cobicistat (Tybost) [6] | HIV | | | human CYP3A protein inhibitor | |
| Combivir (Lamivudine/Zidovudine) | HIV | | | | 1997 (FDA) |
| Daclatasvir (Daklinza) | Hepatitis C | | | NS5A inhibitor | |
| Darunavir | HIV | | antiretroviral | HIV PI | |
| Delavirdine | HIV | | antiretroviral | NNRTI | |
| Descovy (Emtricitabine/tenofovir alafenamide) | Hepatitis B | | | - Emtricitabine: NRTI
- Tenofovir alafenamide: NRTI
| |
| Didanosine | HIV | | | Adenosine analogue RTI | 1991 (FDA) |
| Docosanol | Herpes Simplex | | | Entry inhibitor | 2000 (FDA) |
| Dolutegravir | HIV | | | Integrase inhibitor | |
| Doravirine (Pifeltro) [7] | HIV | Merck & Co | | NNRTI | 2018 (FDA) |
| Edoxudine | Herpes Simplex | | | Thymidine analogue inhibitor | |
| Efavirenz | HIV | Mylan | | NNRTI | 1998 |
| Elvitegravir | HIV | Gilead Sciences | | Integrase inhibitor | |
| Emtricitabine | HIV | Gilead Sciences | | NRTI | 2003 |
| Enfuvirtide | HIV | | | Entry inhibitor | 2003 |
| Ensitrelvir | COVID-19 | Shionogi | | 3C-like protease inhibitor | |
| Entecavir | HIV | | | NRTI | 2005 |
| Etravirine (Intelence) [8] | HIV | | | NNRTI | 2008 |
| Famciclovir | Herpes Zoster | | | Guanosine analogue | 1994 |
| Fomivirsen | AIDS | | Anti-sense oligonucleotide | Anti-sense | - FDA-licensed in 1998
- Withdrawn in EU (2002), US (2006)
|
| Fosamprenavir | HIV | ViiV Healthcare | | Amprenavir pro-drug | 2003 (FDA), 2004 (EMA) |
| Foscarnet | Herpes | | | Pyrophosphate analogue DNA polymerase inhibitor | 1991 |
| Ganciclovir (Cytovene) [9] | Cytomegalovirus (CMV) [10] | | | Competitive nucleoside analogue dGTP inhibitor | 1988 |
| Ibacitabine | Herpes labialis | | | | |
| Ibalizumab (Trogarzo) [11] | HIV | | | Entry inhibitor | 2018 |
| Idoxuridine | Herpes | | | dU analogue inhibitor | 1962 |
| Imiquimod | Genital wart, Basal cell carcinoma, Actinic keratosis | | | Opioid growth factor receptor (OGFr) agonist | 1997 |
| Inosine pranobex | Herpes Simplex | | | Thymus hormone immunostimulant | |
| Indinavir | HIV | | | PI | 1996 |
| Lamivudine | HIV | | | cytidine analogue RTI | |
| Letermovir (Prevymis) [12] | Cytomegalovirus (CMV) | | | | |
| Lopinavir | HIV | | | | |
| Loviride | HIV | | | | |
| Maraviroc | HIV | | | entry inhibitor | |
| Methisazone | Smallpox | | | | |
| Molnupiravir | COVID-19 | Merck & Co. | | viral RNA polymerase inhibitor | |
| Moroxydine | Influenza | | | | |
| Nelfinavir | HIV | | | | |
| Nirmatrelvir/ritonavir (Paxlovid) | COVID-19 | Pfizer | | 3C-like protease inhibitor (Nirmatrelvir) / inhibition of metabolism of nirmatrelvir (ritonavir) | |
| Nevirapine | HIV | | | non-nucleoside reverse transcriptase inhibitor | |
| Nitazoxanide | Broad-spectrum antiviral | | thiazolide | | |
| Norvir | HIV | | | | |
| Oseltamivir (Tamiflu) [13] | Influenza | | | neuraminidase inhibitor | |
| Peramivir (Rapivab) [14] | Influenza | | | | |
| Penciclovir | Herpes | | | | |
| Pleconaril | Picornavirus | Schering-Plough | | | |
| Podophyllotoxin | Genital wart | | | | |
| Raltegravir | HIV | | | Integrase inhibitor | |
| Raphamin | | | | | |
| Remdesivir | COVID-19 | | | viral RNA polymerase inhibitor | |
| Ribavirin | Hepatitis C [15] | | | nucleoside analogue reverse transcriptase inhibitor | |
| Rilpivirine (Edurant) [16] | HIV | | | | |
| Rimantadine | Influenza A | | | M2 proton channel antagonist | |
| Ritonavir | HIV | | | HIV-1 protease inhibitor | |
| Saquinavir | HIV | | | | |
| Simeprevir (Olysio) | Hepatitis C | | | | |
| Sofosbuvir | Hepatitis C [17] | | | nucleoside analogue reverse transcriptase inhibitor | |
| Stavudine | HIV | | | | |
| Taribavirin (Viramidine) | Hepatitis Syndromes in which Ribavirin is active [18] | | | | |
| Telaprevir | Hepatitis C | | | | |
| Telbivudine (Tyzeka) | Hepatitis B | | | | |
| Tenofovir alafenamide | Hepatitis B | | | | |
| Tenofovir disoproxil | Hepatitis B, HIV [19] | | | | |
| Tipranavir | HIV | | | | |
| Trifluridine | Eyes related Herpes | | | | |
| Trizivir | HIV | | | | |
| Tromantadine | Herpes Simplex | | | | |
| Truvada | HIV | | | | |
| Umifenovir | Influenza | | | | |
| Valaciclovir (Valtrex) [20] | Herpes Simplex/Zoster | | | | |
| Valganciclovir (Valcyte) [21] | Cytomegalovirus (CMV) | | | | |
| Vicriviroc | HIV-1 | Schering-Plough | | pyrimidine CCR5 entry inhibitor | |
| Vidarabine | Herpes Simplex, Varicella Zoster | | | | |
| Zalcitabine | HIV | | | | |
| Zanamivir (Relenza) [22] | Influenza A, Influenza B | | | | |
| Zidovudine | HIV [23] | | Antiretroviral | | |